n-3脂肪酸补充治疗干眼病:DREAM随机对照试验
这项多中心双盲随机对照试验将中度至重度干眼病患者随机分配至每日口服3000 mg鱼源n-3二十碳五烯酸和二十二碳六烯酸组或橄榄油安慰剂组,评估12个月内OSDI评分变化。结果显示,活性补充组与安慰剂组的OSDI评分平均变化无显著差异(-13.9分 vs -12.5分,均差-1.9分,95%CI -5.0至1.1,P=0.21),次要结局亦无显著差异。
要点
- 每日3000 mg n-3脂肪酸补充12个月未显著改善干眼病患者的OSDI症状评分。
- 结膜染色、角膜染色、泪膜破裂时间和Schirmer试验等次要结局均无显著差异。
- 活性补充组与安慰剂组不良事件发生率相似。
核心结论
- 在中度至重度干眼病患者中,随机接受每日3000 mg n-3脂肪酸补充12个月者与接受安慰剂者相比,结局无显著改善。
研究设计与样本
- 多中心、双盲临床试验,将中度至重度干眼病患者随机分配至每日口服3000 mg鱼源n-3二十碳五烯酸和二十二碳六烯酸组或橄榄油安慰剂组。
- 活性补充组349例、安慰剂组186例被分配;主要分析分别纳入329例和170例。
- 主要结局为OSDI评分(范围0至100,评分越高症状越重)从基线至6个月和12个月平均值的平均变化。
主要发现
- OSDI评分平均变化在活性补充组为-13.9分、安慰剂组为-12.5分,均差-1.9分(95%CI -5.0至1.1;P=0.21),无显著差异,且在各预设亚组中结果一致。
- 结膜染色评分均差0.0分(95%CI -0.2至0.1)、角膜染色评分均差0.1分(95%CI -0.2至0.4)、泪膜破裂时间均差0.2秒(95%CI -0.1至0.5)、Schirmer试验均差0.0 mm(95%CI -0.8至0.9),均无显著差异。
- 12个月时,根据红细胞n-3脂肪酸水平评估的活性补充组治疗依从率为85.2%。
- 两组不良事件发生率相似。
关键数值与推荐
- OSDI评分范围0至100,评分越高表示症状越严重。
- 结膜染色评分范围0至6,角膜染色评分范围0至15,评分越高表示眼表损伤越重。
- 泪膜破裂时间为眨眼至泪膜出现空隙之间的秒数,Schirmer试验为下眼睑放置纸条的湿润长度,数值越低表示体征越重。
临床怎么用
- 对于中度至重度干眼病患者,每日3000 mg n-3脂肪酸补充12个月未显示出优于安慰剂的症状或体征改善。
- 临床推荐n-3脂肪酸补充治疗干眼病时需考虑本试验的阴性结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dry eye disease is a common chronic condition that is characterized by ocular discomfort and visual disturbances that decrease quality of life. Many clinicians recommend the use of supplements of n-3 fatty acids (often called omega-3 fatty acids) to relieve symptoms. METHODS: In a multicenter, double-blind clinical trial, we randomly assigned patients with moderate-to-severe dry eye disease to receive a daily oral dose of 3000 mg of fish-derived n-3 eicosapentaenoic and docosahexaenoic acids (active supplement group) or an olive oil placebo (placebo group). The primary outcome was the mean change from baseline in the score on the Ocular Surface Disease Index (OSDI; scores range from 0 to 100, with higher scores indicating greater symptom severity), which was based on the mean of scores obtained at 6 and 12 months. Secondary outcomes included mean changes per eye in the conjunctival staining score (ranging from 0 to 6) and the corneal staining score (ranging from 0 to 15), with higher scores indicating more severe damage to the ocular surface, as well as mean changes in the tear break-up time (seconds between a blink and gaps in the tear film) and the result on Schirmer's test (length of wetting of paper strips placed on the lower eyelid), with lower values indicating more severe signs. RESULTS: A total of 349 patients were assigned to the active supplement group and 186 to the placebo group; the primary analysis included 329 and 170 patients, respectively. The mean change in the OSDI score was not significantly different between the active supplement group and the placebo group (-13.9 points and -12.5 points, respectively; mean difference in change after imputation of missing data, -1.9 points; 95% confidence interval [CI], -5.0 to 1.1; P=0.21). This result was consistent across prespecified subgroups. There were no significant differences between the active supplement group and the placebo group in mean changes from baseline in the conjunctival staining score (mean difference in change, 0.0 points; 95% CI, -0.2 to 0.1), corneal staining score (0.1 point; 95% CI, -0.2 to 0.4), tear break-up time (0.2 seconds; 95% CI, -0.1 to 0.5), and result on Schirmer's test (0.0 mm; 95% CI, -0.8 to 0.9). At 12 months, the rate of adherence to treatment in the active supplement group was 85.2%, according to the level of n-3 fatty acids in red cells. Rates of adverse events were similar in the two trial groups. CONCLUSIONS: Among patients with dry eye disease, those who were randomly assigned to receive supplements containing 3000 mg of n-3 fatty acids for 12 months did not have significantly better outcomes than those who were assigned to receive placebo. (Funded by the National Eye Institute, National Institutes of Health; DREAM ClinicalTrials.gov number, NCT02128763 .).
引用
- Asbell PA, Maguire MG, Pistilli M, et al. n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease. N Engl J Med. 2018. PMID: 29652551. doi:10.1056/NEJMoa1709691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。